Vascular and Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Vascular and Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Surgery, Faculty Hospital Kralovske Vinohrady, 3rd Medical Faculty, Charles University, Prague, Czech Republic.
Eur J Vasc Endovasc Surg. 2014 Apr;47(4):444-50. doi: 10.1016/j.ejvs.2014.01.010. Epub 2014 Jan 21.
In 2008, a new technique of reinforced aneurysmorrhaphy with a polyester mesh tube for salvaging true aneurysmal arteriovenous (AV) haemodialysis access was described by us. In this study, the long-term patency and complication rates associated with this procedure were analysed, and the effect of reinforced aneurysmorrhaphy on high-flow vascular access was assessed.
This was a retrospective non-randomised study with prospectively collected data performed at a single centre. Patients with true aneurysmal haemodialysis AV access who underwent aneurysmorrhaphy with external mesh prosthesis between March 2007 and October 2012 were included. Clinical assessment and duplex ultrasound were performed preoperatively, 1, 3, and 12 months postoperatively, and annually thereafter.
Data from 62 patients (median age 60 years, range 28-81 years; 63% men) were analysed. The commonest indication was high-flow vascular access associated with the risk of high output cardiac failure (24 patients, 39%). The mean follow-up time was 14.66 ± 12.80 months. Primary patency rates at 6 and 12 months were 86% and 79% respectively. Assisted primary patency rates at 6 and 12 months were 89% and 80% respectively. In 23 patients (96%) operated on for high-flow vascular access, decreased vascular access flow was observed after the procedure. The average flow reduction after aneurysmorrhaphy was 2,197 mL/minute. Postoperative bleeding and infection necessitating surgical revision occurred in three (4.8%) and three (4.8%) patients respectively.
Reinforced aneurysmorrhaphy with an external mesh prosthesis is an effective method for treating true aneurysmal haemodialysis AV access, with excellent long-term patency and minimal complications due to infection.
2008 年,我们描述了一种新的技术,即使用聚酯网管进行强化动脉瘤缝合,以挽救真性动静脉(AV)血液透析通路的动脉瘤。本研究分析了该技术的长期通畅率和并发症发生率,并评估了强化动脉瘤缝合对高流量血管通路的影响。
这是一项单中心回顾性非随机研究,前瞻性收集数据。纳入 2007 年 3 月至 2012 年 10 月期间接受动脉瘤缝合术和外部网片假体治疗真性动脉瘤性血液透析 AV 通路的患者。术前、术后 1、3 和 12 个月以及此后每年进行临床评估和双功能超声检查。
分析了 62 例患者(中位年龄 60 岁,范围 28-81 岁;63%为男性)的数据。最常见的指征是高流量血管通路,伴有高输出性心力衰竭的风险(24 例,39%)。平均随访时间为 14.66±12.80 个月。术后 6 个月和 12 个月的初始通畅率分别为 86%和 79%。术后 6 个月和 12 个月的辅助初始通畅率分别为 89%和 80%。在 23 例(96%)因高流量血管通路而行手术的患者中,术后观察到血管通路流量减少。动脉瘤缝合术后平均流量减少 2197ml/min。术后出血和感染需手术修正的分别有 3 例(4.8%)和 3 例(4.8%)。
使用外部网片假体进行强化动脉瘤缝合术是治疗真性动脉瘤性血液透析 AV 通路的有效方法,具有极好的长期通畅率和极低的感染相关并发症发生率。